certolizumab pegol vs JNJ-78934804
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Crohn's Disease
Shared mechanism: TNF-alpha · full Crohn's Disease pipeline
certolizumab pegol · Cimzia
Marketed by UCB
NCT00552344 · Phase 3 · completed
This open-label study gave long-term certolizumab pegol to patients with Crohn's disease from study C87085. Its primary objective was safety and its primary outcomes were adverse events, so there is no efficacy result to call met or missed. Over up to 272 weeks, 89.6% of patients had an adverse event and 37.1% a serious one. Source: CT.gov posted results. Its registered primary outcome on ClinicalTrials.gov is "Percentage of Subjects With at Least One Adverse Event (AE) During the Duration of the Study C87088 (up to 272 Weeks)" (with 1 other safety or dose-finding measure). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Reported efficacy
Percentage of Subjects in Clinical Remission at Week 6: Clinical remission at Week 6: 31.6% (95% CI 25.4-37.8) certolizumab pegol vs 25.4% (95% CI 19.5-31.3) placebo; no p-value reported (missed)
Result source: NCT00552058
JNJ-78934804
Developed by Johnson & Johnson
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: June 2028 · NCT07577843 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Crohn's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | certolizumab pegol | JNJ-78934804 |
|---|---|---|
| Clinical remission (induction) | 31.6% vs 25.4%+6.2 vs placeboNCT005520582 other results
| —Trial running · NCT07577843 |
| Endoscopic response (induction) | —Not posted · NCT00152425 | —Trial running · NCT07577843 |
| Clinical remission (maintenance) | 37.5% vs 35%+2.5 vs placeboNCT003564081 other result
| —Trial running · NCT07577843 |
| Endoscopic response (maintenance) | —Not posted · NCT00152425 | —Trial running · NCT07577843 |
Clinical remission (induction)
- certolizumab pegol
- 31.6% vs 25.4%+6.2 vs placeboNCT00552058
2 other results
- 26.5% vs 19.1% NCT00552058
- 23.3% vs 15.8% NCT00552058
- JNJ-78934804
- —Trial running · NCT07577843
Endoscopic response (induction)
- certolizumab pegol
- —Not posted · NCT00152425
- JNJ-78934804
- —Trial running · NCT07577843
Clinical remission (maintenance)
- certolizumab pegol
- 37.5% vs 35%+2.5 vs placeboNCT00356408
1 other result
- 3% vs 35% NCT00356408
- JNJ-78934804
- —Trial running · NCT07577843
Endoscopic response (maintenance)
- certolizumab pegol
- —Not posted · NCT00152425
- JNJ-78934804
- —Trial running · NCT07577843
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
JNJ-78934804: no structured comparison results are available for Crohn's Disease.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. certolizumab pegol: 4 of 4 rows · JNJ-78934804: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | certolizumab pegol |
|---|---|
| Dropout rate | 78.4%a NCT00552344 · Phase 3 · monotherapy show 24 more results80.3% NCT00160524 · Phase 3 · monotherapy —400 mg every 2 weeks NCT00308581 · Phase 3 · monotherapy —400 mg every 4 weeks NCT00308581 · Phase 3 · monotherapy 69.5%400 mg NCT00333788 · Phase 3 · monotherapy · Crohn's Disease · phase 3 92.3% NCT00160706 · Phase 3 · monotherapy —400 mg NCT00356408 · Phase 3 · monotherapy —CDP870/Completer NCT00356408 · Phase 3 · monotherapy —CDP870/Non-completer NCT00356408 · Phase 3 · monotherapy 7.2% NCT00552058 · Phase 3 · monotherapy 40.4%400 mg NCT00297648 · Phase 3 · monotherapy · Crohn's Disease · phase 3 —Q2W NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3 —Q4W NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3 —High-dose (Weight Adjusted) NCT01190410 · Phase 2 · registry result, not featured evidence —Low-dose (Weight Adjusted) NCT01190410 · Phase 2 · registry result, not featured evidence —Re-Induction NCT01190410 · Phase 2 · registry result, not featured evidence 46.2%400 mg / 200 mg NCT00329420 · Phase 2 · registry result, not featured evidence 53.3%400 mg / 400 mg NCT00329420 · Phase 2 · registry result, not featured evidence 26.7%CZP 400 mg / CZP 200 mg NCT00329550 · Phase 2 · registry result, not featured evidence 25%CZP 400 mg / CZP 400 mg NCT00329550 · Phase 2 · registry result, not featured evidence 3.1%400 mg NCT00291668 · Phase 2 · registry result, not featured evidence 3.3%200 mg NCT00291668 · Phase 2 · registry result, not featured evidence 0%400 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence 0%400 mg Q4W NCT04163016 · Phase 1 · registry result, not featured evidence 0%200 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | —a NCT00552344 · Phase 3 · monotherapy show 24 more results35.8% NCT00160524 · Phase 3 · monotherapy —400 mg every 2 weeks NCT00308581 · Phase 3 · monotherapy —400 mg every 4 weeks NCT00308581 · Phase 3 · monotherapy 18.9%400 mg NCT00333788 · Phase 3 · monotherapy · Crohn's Disease · phase 3 51% NCT00160706 · Phase 3 · monotherapy —400 mg NCT00356408 · Phase 3 · monotherapy —CDP870/Completer NCT00356408 · Phase 3 · monotherapy —CDP870/Non-completer NCT00356408 · Phase 3 · monotherapy 3.6% NCT00552058 · Phase 3 · monotherapy 14.6%400 mg NCT00297648 · Phase 3 · monotherapy · Crohn's Disease · phase 3 —Q2W NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3 —Q4W NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3 —High-dose (Weight Adjusted) NCT01190410 · Phase 2 · registry result, not featured evidence —Low-dose (Weight Adjusted) NCT01190410 · Phase 2 · registry result, not featured evidence —Re-Induction NCT01190410 · Phase 2 · registry result, not featured evidence —400 mg / 200 mg NCT00329420 · Phase 2 · registry result, not featured evidence —400 mg / 400 mg NCT00329420 · Phase 2 · registry result, not featured evidence 26.7%CZP 400 mg / CZP 200 mg NCT00329550 · Phase 2 · registry result, not featured evidence 12.5%CZP 400 mg / CZP 400 mg NCT00329550 · Phase 2 · registry result, not featured evidence —400 mg NCT00291668 · Phase 2 · registry result, not featured evidence —200 mg NCT00291668 · Phase 2 · registry result, not featured evidence 0%400 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence 0%400 mg Q4W NCT04163016 · Phase 1 · registry result, not featured evidence 0%200 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 37.1%a NCT00552344 · Phase 3 · monotherapy show 24 more results40.3% NCT00160524 · Phase 3 · monotherapy 13.4%400 mg every 2 weeks NCT00308581 · Phase 3 · monotherapy 13.4%400 mg every 4 weeks NCT00308581 · Phase 3 · monotherapy 31.9%400 mg NCT00333788 · Phase 3 · monotherapy · Crohn's Disease · phase 3 44.5% NCT00160706 · Phase 3 · monotherapy 14.6%400 mg NCT00356408 · Phase 3 · monotherapy 0%CDP870/Completer NCT00356408 · Phase 3 · monotherapy 12.1%CDP870/Non-completer NCT00356408 · Phase 3 · monotherapy 5.4% NCT00552058 · Phase 3 · monotherapy 38.2%400 mg NCT00297648 · Phase 3 · monotherapy · Crohn's Disease · phase 3 0%Q2W NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3 0%Q4W NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3 40%High-dose (Weight Adjusted) NCT01190410 · Phase 2 · registry result, not featured evidence 0%Low-dose (Weight Adjusted) NCT01190410 · Phase 2 · registry result, not featured evidence 50%Re-Induction NCT01190410 · Phase 2 · registry result, not featured evidence 23.1%400 mg / 200 mg NCT00329420 · Phase 2 · registry result, not featured evidence 26.7%400 mg / 400 mg NCT00329420 · Phase 2 · registry result, not featured evidence 33.3%CZP 400 mg / CZP 200 mg NCT00329550 · Phase 2 · registry result, not featured evidence 31.3%CZP 400 mg / CZP 400 mg NCT00329550 · Phase 2 · registry result, not featured evidence 9.4%400 mg NCT00291668 · Phase 2 · registry result, not featured evidence 3.3%200 mg NCT00291668 · Phase 2 · registry result, not featured evidence —400 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence 20%400 mg Q4W NCT04163016 · Phase 1 · registry result, not featured evidence 26.7%200 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | a crohn's disease 31.6% abdominal pain 18.7% upper respiratory tract infection 15.7% NCT00552344 · Phase 3 · monotherapy show 21 more results400 mg every 2 weeks nasopharyngitis 17.2% pyrexia 11.8% arthralgia 10.8% NCT00308581 · Phase 3 · monotherapy 400 mg every 4 weeks headache 16.6% nasopharyngitis 12.3% nausea 11.2% NCT00308581 · Phase 3 · monotherapy 400 mg nasopharyngitis 27.5% headache 20.5% pyrexia 20.5% NCT00333788 · Phase 3 · monotherapy · Crohn's Disease · phase 3 400 mg crohn's disease 21.4% (placebo 7.1%) arthralgia 18.4% (placebo 0%) upper respiratory tract infection 13.6% (placebo 7.1%) NCT00356408 · Phase 3 · monotherapy arthralgia 25% (placebo 0%) myalgia 18.8% (placebo 0%) sinusitis 18.8% (placebo 7.1%) NCT00356408 · Phase 3 · monotherapy crohn's disease 33.3% (placebo 7.1%) arthralgia 21.2% (placebo 0%) nausea 18.2% (placebo 7.1%) NCT00356408 · Phase 3 · monotherapy headache 5.4% (placebo 4.7%) abdominal pain 4.5% (placebo 3.7%) arthralgia 4% (placebo 2.8%) NCT00552058 · Phase 3 · monotherapy 400 mg headache 33.7% arthralgia 30.3% nasopharyngitis 23.6% NCT00297648 · Phase 3 · monotherapy · Crohn's Disease · phase 3 High-dose (Weight Adjusted) abdominal pain upper 40% nasopharyngitis 20% nausea 20% NCT01190410 · Phase 2 · registry result, not featured evidence Low-dose (Weight Adjusted) asthma exercise induced 25% cough 25% dizziness 25% NCT01190410 · Phase 2 · registry result, not featured evidence Re-Induction abdominal injury 50% anal fissure 50% c-reactive protein increased 50% NCT01190410 · Phase 2 · registry result, not featured evidence 400 mg / 200 mg pyrexia 46.2% (placebo 11.1%) nasopharyngitis 38.5% (placebo 55.6%) contusion 15.4% (placebo 0%) NCT00329420 · Phase 2 · registry result, not featured evidence 400 mg / 400 mg nasopharyngitis 40% (placebo 55.6%) pyrexia 20% (placebo 11.1%) nausea 13.3% (placebo 5.6%) NCT00329420 · Phase 2 · registry result, not featured evidence nasopharyngitis 20% (placebo 22.2%) nausea 13.3% (placebo 22.2%) urinary tract infection 13.3% (placebo 0%) NCT00329550 · Phase 2 · registry result, not featured evidence nasopharyngitis 62.5% (placebo 22.2%) dna antibody positive 12.5% (placebo 22.2%) headache 12.5% (placebo 0%) NCT00329550 · Phase 2 · registry result, not featured evidence 400 mg nasopharyngitis 21.9% (placebo 31.3%) nausea 6.3% (placebo 3.1%) pharynx discomfort 6.3% (placebo 0%) NCT00291668 · Phase 2 · registry result, not featured evidence 200 mg nasopharyngitis 23.3% (placebo 31.3%) nausea 6.7% (placebo 3.1%) pharyngolaryngeal pain 6.7% (placebo 0%) NCT00291668 · Phase 2 · registry result, not featured evidence 400 mg Q4W influenza 40% cystitis 20% foetal vascular malperfusion 20% NCT04163016 · Phase 1 · registry result, not featured evidence 200 mg Q2W covid-19 40% headache 20% hypertension 13.3% NCT04163016 · Phase 1 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 21 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
certolizumab pegol
show 2 more results
show 2 more results
show 1 more result
show 1 more result
show 1 more result
show 19 more results
show 19 more results
show 1 more result
show 17 more results
show 17 more results
show 2 more results
+ 28 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: certolizumab pegol's landscape · JNJ-78934804's landscape